ResearcherHumboldt-Universität zu BerlinActive in the last 2 years
Nina A. Hering
Matched on ORCID iD 0000-0001-9751-6967; OpenAlex author ID A5070875274. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper
Papers 4
- Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-025-01128-8↗
- Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. First author DOI 10.1007/s00432-022-04518-9↗
- Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer. Co-author DOI 10.3390/cancers15020456↗
- Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Co-author DOI 10.1007/s13402-020-00559-9↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ioannis Pozios · 4 shared papers, 2021–2025 · strength 0.72
- Paper Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signal… DOI 10.1007/s13402-025-01128-8↗
- Paper Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Ca… DOI 10.3390/cancers15020456↗
- Paper Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. DOI 10.1007/s00432-022-04518-9↗
- Hendrik Seeliger · 4 shared papers, 2021–2025 · strength 0.72
- Paper Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signal… DOI 10.1007/s13402-025-01128-8↗
- Paper Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Ca… DOI 10.3390/cancers15020456↗
- Paper Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. DOI 10.1007/s00432-022-04518-9↗
- Christiane J. Bruns · 3 shared papers, 2021–2025 · strength 0.54
- Paper Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signal… DOI 10.1007/s13402-025-01128-8↗
- Paper Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. DOI 10.1007/s00432-022-04518-9↗
- Paper Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. DOI 10.1007/s13402-020-00559-9↗
- Katharina Beyer · 2 shared papers, 2023 · strength 0.36
- Peter Čamaj · 2 shared papers, 2021–2025 · strength 0.36
- Paper Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signal… DOI 10.1007/s13402-025-01128-8↗
- Paper Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. DOI 10.1007/s13402-020-00559-9↗
- Lucas D. Lee · 2 shared papers, 2021–2025 · strength 0.36
- Paper Correction to: Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signal… DOI 10.1007/s13402-025-01128-8↗
- Paper Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. DOI 10.1007/s13402-020-00559-9↗
- Thomas Knösel · 1 shared paper, 2023 · strength 0.18
- Georgios Antonios Margonis · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.